학술논문
Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)
Document Type
Academic Journal
Author
Curigliano, Giuseppe; Hu, Xichun; Dent, Rebecca Alexandra; Yonemori, Kan; Barrios Sr., Carlos H.; O'Shaughnessy, Joyce; Wildiers, Hans; Zhang, Qingyuan; Im, Seock-Ah; Saura, Cristina; Biganzoli, Laura; Sohn, Joohyuk; Levy, Christelle; Jacot, William; Begbie, Natasha; Ke, Jun; Patel, Gargi Surendra; Bardia, Aditya
Source
Subject
Language
English
ISSN
0732-183X